Method for enhancing stem cell trafficking

• US 8,414,881 B2
• Filed: 09/07/2011
• Issued: 04/09/2013
• Est. Priority Date: 05/14/2001
• Status: Active Grant

• Current Assignee: Desert Lake Technologies, LLC
• Original Assignee: Desert Lake Technologies, LLC
• Inventors: Jensen, Gitte S., Drapeau, Christian
• Primary Examiner(s): Afremova, Vera
• Application Number:
  US13/227,323
• Publication Number:
  US 20110318310A1
• Time in Patent Office: 580 Days
• Field of Search: None
• US Class Current: 424/93.1
• CPC Class Codes: A61K 35/748 Cyanobacteria, i.e. blue-green bacteria or blue-green algae, e.g. spirulina algae, microalgae or microphytes A61K36/02
• CPC Class Codes: A61P 1/16 for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• CPC Class Codes: A61P 19/02 for joint disorders, e.g. arthritis, arthrosis
• CPC Class Codes: A61P 19/10 for osteoporosis
• CPC Class Codes: A61P 21/00 Drugs for disorders of the muscular or neuromuscular system
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 25/16 Anti-Parkinson drugs
• CPC Class Codes: A61P 25/28 for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61P 9/00 Drugs for disorders of the cardiovascular system
• CPC Class Codes: A61P 9/10 for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• CPC Class Codes: Y10S 435/946 using algae

Abstract

Consumption of blue-green algae, or extracts thereof, enhances trafficking or homing of stem cells in animals by inducing a transient increase in the population of stem cells present in the animal'"'"'s circulatory system. The animal may be healthy or suffering some disease or physiological condition.

Claims

1. A method for enhancing stem cell trafficking in a subject, comprising:

selecting a subject with a disease or physiological condition, wherein the disease or physiological condition is cardiac infarction; and

administering to the subject a therapeutically effective amount of Aphanizomenon flos aquae,

thereby enhancing stem cell trafficking in the subject.

2. The method according to claim 1, wherein the subject is a mammal.

3. The method according to claim 1, wherein the subject is a human.

4. The method according to claim 1, wherein the Aphanizomenon flos aquae is administered as dried whole cells.

5. The method according to claim 1, wherein the Aphanizomenon flos aquae is administered as liquid fresh or frozen whole cells.

6. The method according to claim 1, wherein stem cell trafficking is increased about 100% to about 500% as compared to a control.

7. The method according to claim 1, wherein the stem cell is a CD34+ cell.

8. The method according to claim 1, further comprising measuring CD34+ stem cells in the subject.

9. A method for enhancing stem cell homing in a subject, comprising:

selecting a subject with a disease or physiological condition, wherein the disease or physiological condition is cardiac infarction; and

administering to the subject a therapeutically effective amount of Aphanizomenon flos aquae,

thereby enhancing stem cell homing in the subject.

10. The method according to claim 9, wherein the subject is a mammal.

11. The method according to claim 9, wherein the subject is a human.

12. The method according to claim 9, wherein the Aphanizomenon flos aquae is administered as dried whole cells.

13. The method according to claim 9, wherein the Aphanizomenon flos aquae is administered as liquid fresh or frozen whole cells.

14. The method according to claim 9, wherein stem cell homing is increased about 100% to about 500% as compared to a control.

15. The method according to claim 9, wherein the stem cell is a CD34+ cell.

16. The method according to claim 9, further comprising measuring CD34+ stem cells in the subject.

17. A method of treating a subject with a disease amenable to treatment with stem cells, comprising:

selecting a subject with a disease amenable to treatment with stem cells, wherein the disease is cardiac infarction; and

administering to the subject a therapeutically effective amount of Aphanizomenon flos aquae,

thereby treating the disease.